H. Robert Superko/a4m.com
Aug 11, 2025, 06:08
New Data From WHS and ASPREE: Aspirin Heart Disease Prevention Conundrum
Maxima Mendez, Cardiologist, CEO of Cli-Lipid and the Cardiovascular Lipid Club, shared a post on X:
“New data from WHS and ASPREE:
Aspirin and Lpa
•LPA+ genotype → higher CVD risk, aspirin reduced events significantly (NNT: 38–34)
•LPA– genotype → normal CVD risk, bleeding risk outweighs benefit (NNT: 833–250)”
Read the full article here.
Article: The aspirin heart disease prevention conundrum
Authors: H. Robert Superko, John Sninsky, Brenda Garrett․
Stay updated with Hemostasis Today.
-
May 28, 2026, 09:16Maxime Dely: The Human Connection Behind Stem Cell Donation
-
May 28, 2026, 09:15Heghine Khachatryan: Maternal Health Begins With Recognizing Iron Deficiency Early
-
May 28, 2026, 09:15Alejandro González Veliz: Why Cardiovascular Prevention Matters More Than Intervention
-
May 28, 2026, 05:29Kidist K.: First Balloon Pulmonary Angioplasty Performed as New CTEPH Program Launches
-
May 28, 2026, 04:59Maria Sol Andres: Exploring Lipid Disorders in Modern Cancer Care
-
May 28, 2026, 04:42Francesca Granata: Representing the Porphyria Community at the 79th World Health Assembly
-
May 28, 2026, 04:29Samone Cook: When Collaboration Turns Into Organizational Coagulation
-
May 28, 2026, 03:42Lara Bloom: 15,000 Steps, Countless Conversations – One Unforgettable WHA79
-
May 27, 2026, 23:00Octavio Marques Pontes-Neto: Exchanging Latin American Experiences at the Global Stroke Alliance Meeting in Buenos Aires